Teruyuki Sano, PhD

Assistant Professor

Department of Microbiology and Immunology

College of Medicine

Research Program

Translational Oncology Program (TO)

Phone: (312) 996-2270

Email: [email protected]

Gut microbiome has been recognized as promotors to increase the anti-tumor immunity during the checkpoint inhibitor treatments. On the other hand, gut microbiome can be highly associated with tissue inflammation including autoimmune and inflammatory diseases. Our goals are to categorize human microbiome to 1) promote anti-tumor immunity and 2) contribute to the treatment-induced immune related adverse events (irAE).

Disease Focus

Brain; Gastrointestinal; Colorectal

Research Keywords

Microbiome; Treatment-induced Immune Related Adverse Events (irae); Checkpoint Inhibitor; Tumor Immunity; Tissue Inflammation; T Cells
Translate »